DAPK2 is a novel modulator of TRAIL-induced apoptosis

Cell Death and Differentiation

Volumn 21, Issue 11, 2014, Pages 1780-1791

  Schlegel, C R ^a   Fonseca, A V ^a,b   Stocker S ^a,c   Georgiou, M L ^a   Misterek, M B ^a,d   Munro, C E ^a   Carmo, C R ^a,e   Seckl, M J ^a   Costa Pereira, A P ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

^b NATIONAL INSTITUTE FOR MEDICAL RESEARCH   (United Kingdom)

^c GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^d OTTO VON GUERICKE UNIVERSITY   (Germany)

^e INSTITUTO GULBENKIAN DE CIÊNCIA   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

DEATH ASSOCIATED PROTEIN KINASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR;

APOPTOSIS; HUMAN; METABOLISM; PHYSIOLOGY; TUMOR CELL LINE;

APOPTOSIS; CELL LINE, TUMOR; DEATH-ASSOCIATED PROTEIN KINASES; HUMANS; NF-KAPPA B; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND;

EID: 84932185402     PISSN: 13509047     EISSN: 14765403     Source Type: Journal    
DOI: 10.1038/cdd.2014.93     Document Type: Article

References (32)

1. Wiley SR, Schooley K, Smolak PJ, Din WS, Huang CP, Nicholl JK et al. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 1995; 3: 673-682.
2. Pitti RM, Marsters SA, Ruppert S, Donahue CJ, Moore A, Ashkenazi A. Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J Biol Chem 1996; 271: 12687-12690.
3. Falschlehner C, Ganten TM, Koschny R, Schaefer U, Walczak H. TRAIL and other TRAIL receptor agonists as novel cancer therapeutics. Adv Exp Med Biol 2009; 647: 195-206.
4. Walczak H, Miller RE, Ariail K, Gliniak B, Griffith TS, Kubin M et al. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med 1999; 5: 157-163.
5. Walczak H, Degli-Esposti MA, Johnson RS, Smolak PJ, Waugh JY, Boiani N et al. TRAILR2: a novel apoptosis-mediating receptor for TRAIL. EMBO J 1997; 16: 5386-5397.
6. Pan G, O'Rourke K, Chinnaiyan AM, Gentz R, Ebner R, Ni J et al. The receptor for the cytotoxic ligand TRAIL. Science 1997; 276: 111-113.
7. Gonzalvez F, Ashkenazi A. New insights into apoptosis signaling by Apo2L/TRAIL. Oncogene 2010; 29: 4752-4765.
8. Screaton GR, Mongkolsapaya J, Xu XN, Cowper AE, McMichael AJ, JI Bell. TRICK2 a new alternatively spliced receptor that transduces the cytotoxic signal from TRAIL. Curr Biol 1997; 7: 693-696.
9. Mellier G, Huang S, Shenoy K, Pervaiz S. TRAILing death in cancer. Mol Aspects Med 2010; 31: 93-112.
10. Bialik S, Kimchi A. The death-associated protein kinases: structure, function, and beyond. Annu Rev Biochemis 2006; 75: 189-210.
11. Raval A, Tanner SM, Byrd JC, Angerman EB, Perko JD, Chen SS et al. Downregulation of death-associated protein kinase 1 (DAPK1) in chronic lymphocytic leukemia. Cell 2007; 129: 879-890.
12. Kawai T, Nomura F, Hoshino K, Copeland NG, Gilbert DJ, Jenkins NA et al. Death-associated protein kinase 2 is a new calcium/calmodulin-dependent protein kinase that signals apoptosis through its catalytic activity. Oncogene 1999; 18: 3471-3480.
13. Inbal B, Shani G, Cohen O, Kissil JL, Kimchi A. Death-associated protein kinase-related protein 1, a novel serine/threonine kinase involved in apoptosis. Mol Cell Biol 2000; 20: 1044-1054.
14. Inbal B, Bialik S, Sabanay I, Shani G, Kimchi A. DAP kinase and DRP-1 mediate membrane blebbing and the formation of autophagic vesicles during programmed cell death. J Cell Biol 2002; 157: 455-468.
15. Bonito NA, Drechsler J, Stoecker S, Carmo CR, Seckl MJ, Hermanns HM et al. Control of gp130 expression by the mitogen-activated protein kinase ERK2. Oncogene 2014; 33: 2255-2263.
16. Watling D, Carmo CR, Kerr IM, Costa-Pereira AP. Multiple kinases in the interferon-gamma response. Proc Natl Acad Sci USA 2008; 105: 6051-6056.
17. Degli-Esposti MA, Smolak PJ, Walczak H, Waugh J, Huang CP, DuBose RF et al. Cloning and characterization of TRAIL-R3, a novel member of the emerging TRAIL receptor family. J Exp Med 1997; 186: 1165-1170.
18. Emery JG, McDonnell P, Burke MB, Deen KC, Lyn S, Silverman C et al. Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. J Biol Chem 1998; 273: 14363-14367.
19. Shetty S, Graham BA, Brown JG, Hu X, Vegh-Yarema N, Harding G et al. Transcription factor NF-kappaB differentially regulates death receptor 5 expression involving histone deacetylase 1. Mol Cell Biol 2005; 25: 5404-5416.
20. Ganten TM, Haas TL, Sykora J, Stahl H, Sprick MR, Fas SC et al. Enhanced caspase-8 recruitment to and activation at the DISC is critical for sensitisation of human hepatocellular carcinoma cells to TRAIL-induced apoptosis by chemotherapeutic drugs. Cell Death Differen 2004; 11(Suppl 1): S86-S96.
21. Sinicrope FA, Penington RC, Tang XM. Tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis is inhibited by Bcl-2 but restored by the small molecule Bcl-2 inhibitor, HA 14-1, in human colon cancer cells. Clin Cancer Res 2004; 10: 8284-8292.
22. Huang S, Sinicrope FA. BH3 mimetic ABT-737 potentiates TRAIL-mediated apoptotic signaling by unsequestering Bim and Bak in human pancreatic cancer cells. Cancer Res 2008; 68: 2944-2951.
23. Kandasamy K, Kraft AS. Proteasome inhibitor PS-341 (VELCADE) induces stabilization of the TRAIL receptor DR5 mRNA through the 3'-untranslated region. Mol Cancer Therap 2008; 7: 1091-1100.
24. Mendoza FJ, Ishdorj G, Hu X, Gibson SB. Death receptor-4 (DR4) expression is regulated by transcription factor NF-kappaB in response to etoposide treatment. Apoptosis 2008; 13: 756-770.
25. Bernard D, Quatannens B, Vandenbunder B, Abbadie C. Rel/NF-kappaB transcription factors protect against tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL)-induced apoptosis by up-regulating the TRAIL decoy receptor DcR1. J Biol Chem 2001; 276: 27322-27328.
26. Zender L, Hutker S, Mundt B, Waltemathe M, Klein C, Trautwein C et al. NFkappaB-mediated upregulation of bcl-xl restrains TRAIL-mediated apoptosis in murine viral hepatitis. Hepatology 2005; 41: 280-288.
27. Degli-Esposti MA, Dougall WC, Smolak PJ, Waugh JY, Smith CA, Goodwin RG. The novel receptor TRAIL-R4 induces NF-kappaB and protects against TRAILmediated apoptosis, yet retains an incomplete death domain. Immunity 1997; 7: 813-820.
28. Tergaonkar V. NFkappaB pathway: a good signaling paradigm and therapeutic target. Int J Bioch Cell Biol 2006; 38: 1647-1653.
29. Yoo HJ, Byun HJ, Kim BR, Lee KH, Park SY, Rho SB. DAPk1 inhibits NF-kappaB activation through TNF-alpha and INF-gamma-induced apoptosis. Cell Signal 2012; 24: 1471-1477.
30. Chuang YT, Fang LW, Lin-Feng MH, Chen RH, Lai MZ. The tumor suppressor deathassociated protein kinase targets to TCR-stimulated NF-kappa B activation. J Immunol 2008; 180: 3238-3249.
31. Gozuacik D, Kimchi A. DAPk protein family and cancer. Autophagy 2006; 2: 74-79.
32. Sprick MR, Weigand MA, Rieser E, Rauch CT, Juo P, Blenis J et al. FADD/MORT1 and caspase-8 are recruited to TRAIL receptors 1 and 2 and are essential for apoptosis mediated by TRAIL receptor 2. Immunity 2000; 12: 599-609.